Skip to main content

Advertisement

SpringerLink
Log in

Extended survival of a HER-2-positive metastatic breast cancer patient with brain metastases also treated with intrathecal trastuzumab

  • Short Communication
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Slamon DJ, Leyland-Jones B, Shak S et al (2001) Use of chemotherapy plus a monoclonal antibody against HER 2 for metastatic breast cancer that overexpresses HER 2. N Engl J Med 344:783–792

    Article  PubMed  CAS  Google Scholar 

  2. Stemmler HJ, Schmitt M, Willems A et al (2007) Ratio of trastuzumab in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood-brain barrier. Anti-Cancer Drug 18:23–28

    Article  CAS  Google Scholar 

  3. Geyer CE, Forster J, Lindquist D et al (2006) Lapatinib plus capecitabine for HER-2 positive advanced breast cancer. N Engl J Med 355:2733–2743

    Article  PubMed  CAS  Google Scholar 

  4. Clayton AJ, Danson S, Jolly S et al (2004) Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer. Br J Cancer 91:639–643

    PubMed  CAS  Google Scholar 

  5. Gori S, Rimondini S, De Angelis V et al (2007) Central nervous system metastases in HER2 positive metastatic breast cancer patients treated with trastuzumab: incidence, survival, and risk factors. The Oncologist 12:766–773

    Article  PubMed  Google Scholar 

  6. Bendell JC, Domcheck SM, Burstein HJ et al (2003) Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer 97:2972–2977

    Article  PubMed  Google Scholar 

  7. Lai R, Dang CT, Malkin MG, Abrey LE (2004) The risk of central nervous system metastases after trastuzumab therapy in patients with breast carcinoma. Cancer 101:810–816

    Article  PubMed  CAS  Google Scholar 

  8. Shmueli E, Wigler N, Inbar M (2004) Central nervous system progression among patients with metastatic breast cancer responding to trastuzumab treatment. Eur J Cancer 40:379–382

    Article  PubMed  CAS  Google Scholar 

  9. Metro G, Sperduti I, Russillo M et al (2007) Clinical utility of continuing trastuzumab beyond brain progression in HER-2 positive metastatic breast cancer. Oncologist 12:1467–1469

    Article  PubMed  Google Scholar 

  10. Gori S, De Angelis V, Colozza M et al (2007) In reply. Oncologist 12:1469–1471

    Article  Google Scholar 

  11. Grossi PM, Ochiai H, Archer GE et al (2003) Efficacy of intracerebral microinfusion of trastuzumab in an athymic rat model of intracerebral metastatic breast cancer. Clin Cancer Res 9:5514–5520

    PubMed  CAS  Google Scholar 

  12. Laufman LR, Forsthoefel KF (2001) Use of intrathecal trastuzumab in a patient with carcinomatous meningitis. Clin Breast Cancer 2:235

    PubMed  CAS  Google Scholar 

  13. Stemmler HJ, Schmitt M, Harbeck N et al (2006) Application of intrathecal trastuzumab (Herceptin trade mark) for treatment of meningeal carcinomatosis in HER 2 overexpressing metastatic breast cancer. Oncol Rep 15:1373–1377

    PubMed  CAS  Google Scholar 

  14. Platini C, Long J, Walter S (2006) Meningeal carcinomatosis from breast cancer treated with intrathecal trastuzumab. Lancet Oncol 7:778–780

    Article  PubMed  Google Scholar 

  15. Stemmler HJ, Mengele K, Schmitt M et al (2008) Intrathecal trastuzumab (herceptin) and methotrexate for meningeal carcinomatosis in HER2 overexpressing metastatic breast cancer: a case report. Anticancer Drug 19:832–836

    Article  CAS  Google Scholar 

  16. Fouladi M, Chintagumpala M, Laningham FH et al (2006) White matter lesions detected by magnetic resonance imaging after radiotherapy in children with medulloblastoma or primitive neuroectodermal tumor. J Clin Oncol 22:4551–4560

    Article  Google Scholar 

  17. Gori S, Sidoni A, Colozza M et al (2007) EGFR, MAPK, and Akt status by immunohisochemistry (IHC) are not correlated with clinical outcome in HER-2 positive (HER2 +) metastatic breast cancer (MBC) patients (pts) treated with trastuzumab (T) with or without chemotherapy (CT). J Clin Oncol Suppl 25:54s (abstract 1090)

    Google Scholar 

  18. Nahta R, Yu D, Hung M-C et al (2006) Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nat Clin Pract Oncol 3:269–280

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. S.C. Oncologia, Azienda Ospedaliera, Perugia, Italy

    Mariantonietta Colozza, Elisa Minenza & Stefania Gori

  2. Servizio di Anatomia Patologica, Azienda Ospedaliera, Perugia, Italy

    Daniela Fenocchio

  3. Laboratorio Preparazione Farmaci Antiblastici, Azienda Ospedaliera, Perugia, Italy

    Cristina Paolucci

  4. Istituto di Radioterapia, Azienda Ospedaliera, Perugia, Italy

    Cynthia Aristei

  5. S.C. Neuroradiologia, Azienda Ospedaliera, Perugia, Italy

    Piero Floridi

Authors
  1. Mariantonietta Colozza
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Elisa Minenza
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Stefania Gori
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Daniela Fenocchio
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Cristina Paolucci
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Cynthia Aristei
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Piero Floridi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mariantonietta Colozza.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Colozza, M., Minenza, E., Gori, S. et al. Extended survival of a HER-2-positive metastatic breast cancer patient with brain metastases also treated with intrathecal trastuzumab. Cancer Chemother Pharmacol 63, 1157–1159 (2009). https://doi.org/10.1007/s00280-008-0859-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-008-0859-7

Keywords

Search

Navigation